Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Fungal Infection Reports
Erschienen in: Current Fungal Infection Reports 3/2017

21.06.2017 | Current Management of Fungal Infections (M Miceli, Section Editor)

Treatment of the Midwestern Endemic Mycoses, Blastomycosis and Histoplasmosis

verfasst von: Carol A. Kauffman

Erschienen in: Current Fungal Infection Reports | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The purpose of this review is to assess the recommended treatment regimens for the major endemic mycoses, histoplasmosis and blastomycosis, which occur in the Midwestern USA and to provide information about the use of newer antifungal agents for these diseases.

Recent Findings

The basic approach to treatment of histoplasmosis and blastomycosis outlined in the IDSA Guidelines is helpful in managing these diseases. However, changes since these guidelines were published provide safer and better tolerated treatment regimens. Prolonged treatment with amphotericin B is rarely required, and lipid formulations of this drug have largely replaced the amphotericin B deoxycholate formulation. Although no clinical trials have been performed and the data are anecdotal, voriconazole and posaconazole are increasingly used in patients who cannot tolerate itraconazole. Voriconazole is especially useful when central nervous system infection is present. Posaconazole tablets provide consistently appropriate serum levels and the drug is well tolerated.

Summary

New azole agents provide alternative therapeutic options for histoplasmosis and blastomycosis.
Literatur
1.
Li RK, Ciblak MA, Nordoff N, Pasarell L, Warnock DW, McGinnis MR. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob Agents Chemother. 2000;44:1734–6.CrossRefPubMedPubMedCentral
2.
Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol. 1998;36:2950–6.PubMedPubMedCentral
3.
Miceli MH, Kauffman CA. Isavuconazole: a new broad-spectrum triazole antifungal agent. Clin Infect Dis. 2015;61:1558–65.CrossRefPubMed
4.
5.
• Smith JA, Gauthier G. New developments in blastomycosis. Sem Respir Crit Care Med 2015;36:715–28. Well-written overview of pathogenesis, clinical aspects, and treatment of blastomycosis.
6.
Chapman SW, Dismukes WE, Proia LA, Bradsher RW, Pappas PG, Threlkeld MG, Kauffman CA. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:1801–12.CrossRefPubMed
7.
Pappas PG, Bradsher RW, Chapman SW, Kauffman CA, Dine A, Cloud GA, et al. Treatment of blastomycosis with fluconazole: a pilot study. Clin Infect Dis. 1995;20:267–71.CrossRefPubMed
8.
Lemos LB, Baliga M, Guo M. Acute respiratory distress syndrome and blastomycosis: presentation of nine cases and review of the literature. Ann Diagn Pathol. 2001;5:1–9.CrossRefPubMed
9.
Vasquez JE, Mehta JB, Agrawal R, Sarubbi FA. Blastomycosis in northeast Tennessee. Chest. 1998;114:436–43.CrossRefPubMed
10.
Kralt D, Light B, Cheang M, MacNair T, Wiebe L, Limerick B, et al. Clinical characteristics and outcomes in patients with pulmonary blastomycosis. Mycopathologia. 2009;167:115–24.CrossRefPubMed
11.
Lahm T, Neese S, Thornburg AT, Ober MD, Sarosi GA, Hage CA. Corticosteroids for blastomycosis-induced ARDS: a report of two patients and review of the literature. Chest. 2008;33:1478–80.CrossRef
12.
Plamondon M, Lamontagne F, Allard C, Pepin J. Corticosteroids as adjunctive therapy in severe blastomycosis-induced acute respiratory distress syndrome in an immunosuppressed patient. Clin Infect Dis. 2010;51:e1–3.CrossRefPubMed
13.
Dalton HJ, Hertzog JH, Hannan RL, Vezza P, Hauser GJ. Extracorporeal membrane oxygenation for overwhelming Blastomyces dermatitidis pneumonia. Crit Care. 1999;3:91–4.CrossRefPubMedPubMedCentral
14.
• Bednarczyk JM, Kethireddy S, White CW, Freed DH, Singal RK, Bell D, et al. Extracorporeal membrane oxygenation for blastomycosis-related acute respiratory distress syndrome: a case series. Can J Anesth. 2015;62:807–15. The manuscript details the extensive experience in Manitoba using ECMO for patients with severe blastomycosis and ARDS. CrossRefPubMed
15.
Bariola JR, Perry P, Pappas PG, Proia L, Shealey W, Wright PW, et al. Blastomycosis of the central nervous system: a multicenter review of diagnosis and treatment in the modern era. Clin Infect Dis. 2010;50:797–804.CrossRefPubMed
16.
Bush JW, Wuerz T, Embil JM, Del Bigio MR, McDonaldPJ KS. Outcomes of persons with blastomycosis involving the central nervous system. Diagn Microbiol Infect Dis. 2013;76:175–81.CrossRefPubMed
17.
Lentnek AL, Lentnek IA. Successful management of Blastomyces dermatitidis meningitis. Infect Med. 2006;23:39–41.
18.
Borgia SM, Fuller JD, Sarabia A, El-Helou P. Cerebral blastomycosis: a case series incorporating voriconazole in the treatment regimen. Med Mycol. 2006;44:659–64.CrossRefPubMed
19.
Bakleh M, Aksamit AJ, Tleyjeh IM, Marshall WF. Successful treatment of cerebral blastomycosis with voriconazole. Clin Infect Dis. 2005;40:e69–71.CrossRefPubMed
20.
Panicker J, Walsh T, Kamani N. Recurrent central nervous system blastomycosis in an immunocompetent child treated successfully with sequential liposomal amphotericin B and voriconazole. Pediatr Infect Dis J. 2006;25:377–9.CrossRefPubMed
21.
Freifeld A, Proia LA, Andes D, Baddour LM, Blair J, Spellberg B, et al. Voriconazole use for endemic fungal infections. Antimicrob Agents Chemother. 2009;53:1648–51.CrossRefPubMedPubMedCentral
22.
Vindenes T, Gardiner BJ, Nierenberg N, Volpe G. Pneumonia, septic arthritis, and brain abscess in a construction worker. Clin Infect Dis. 2015;60:1684–5.CrossRef
23.
Anderson RJ, Stevens PM, Miller FH, Noskin GA. Fever, progressive nonproductive cough, and headache. Infect Dis Clin Pract. 2005;13:127–31.CrossRef
24.
Harley WB, Lomis M, Haas DW. Marked polymorphonuclear pleocytosis due to blastomycotic meningitis: case report and review. Clin Infect Dis. 1994;18:816–8.CrossRefPubMed
25.
26.
Pearson GJ, Chin TW, Fong IW. Case report: treatment of blastomycosis with fluconazole. Am J Med Sci. 1992;303:313–5.CrossRefPubMed
27.
Pappas PG, Threlkeld MG, Bedsole GD, Cleveland KO, Gelfand MS, Dismukes WE. Blastomycosis in immunocompromised patients. Medicine (Baltimore). 1993;72:311–25.CrossRef
28.
Proia L, Miller R. AST Infectious Diseases Community of Practice. Endemic fungal infections in solid organ transplant recipients. Am J Transpl. 2009;9(suppl 4):S199–207.CrossRef
29.
Gauthier GM, Safdar N, Klein BS, Andes DR. Blastomycosis in solid organ transplant recipients. Transpl Infect Dis. 2007;9:310–7.CrossRefPubMed
30.
• Kauffman CA, Freifeld AG, Andes DR, Baddley JW, Herwaldt L, Walker RC, et al. Endemic fungal infections in solid organ and hematopoietic cell transplant recipients enrolled in the Transplant-Associated Infection Surveillance Network (TRANSNET). Transpl Infect Dis 2014;16:213–24. A multi-center study of endemic mycoses among transplant patients that defines the epidemiology of these infections in this population, details risk factors associated with these infections, and assesses therapy and outcome.
31.
Linder KA, Kauffman CA, Miceli MH. Pulmonary blastomycosis in a hematopoietic cell transplant recipient. Infect Dis Clin Pract. 2016;24:e71–3.CrossRef
32.
33.
Day SR, Weiss DB, Hazen KC, Moore CC. Successful treatment of osseous blastomycosis without pulmonary or disseminated disease and review of the literature. Diagn Microbiol Infect Dis. 2014;79:242–4.CrossRefPubMedPubMedCentral
34.
•• Thompson GR, Rendon A, Ribeiro dos Santos R, Queiroz-Telles F, Ostrosky-Zeichner L, Azie N, et al. Isavuconazole treatment of cryptococcosis and dimorphic mycoses. Clin Infect Dis 2016;63:356–62. This paper provides the only data currently available on the use of isavuconazole for the endemic mycoses. Unfortunately, very few patients with histoplasmosis and blastomycosis have been treated with isavuconazole.
35.
36.
Wheat LJ, Freifeld AG, Kleiman MG, Baddley JW, McKinsey DS, Loyd JE, Kauffman CA. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45:807–27.CrossRefPubMed
37.
• Hage CA, Azar MM, Bahr N, Loyd J, Wheat LJ. Histoplasmosis: up-to-date evidence-based approach to diagnosis and management. Rem Respir Crit Care Med. 2015;36:729–45. A nice review of diagnosis and treatment of all forms of histoplasmosis. CrossRef
38.
Parish JM, Rosenow EC. Mediastinal granuloma and mediastinal fibrosis. Sem Respir Crit Care Med. 2001;23:135–43.CrossRef
39.
Peikert T, Colby TV, Midthun DE, Pairolero PC, Edell ES, Schroeder DR, et al. Fibrosing mediastinitis: clinical presentation, therapeutic outcomes, and adaptive immune response. Medicine (Baltimore). 2011;90:412–23.CrossRef
40.
Albers EL, Pugh ME, Hill KD, Wang L, Loyd JE, Doyle TP. Percutaneous vascular stent implantation as treatment for central vascular obstruction due to fibrosing mediastinitis. Circulation. 2011;123:1391–9.CrossRefPubMedPubMedCentral
41.
Johnson PC, Wheat LJ, Cloud GA, Goldman M, Lancaster D, Bamberger DM, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med. 2002;137:105–9.CrossRefPubMed
42.
• Riddell J, Kauffman CA, Smith JA, Assi M, Blue S, Buitrago MI, et al. Histoplasma capsulatum endocarditis: multicenter case series with review of current diagnostic techniques and treatment. Medicine (Baltimore). 2014;93:186–93. An in-depth review of histoplasma endocarditis. CrossRef
43.
Schestatsky P, Chedid MF, Amaral OB, Unis G, Oliveira FM, Severo LC. Isolated central nervous system histoplasmosis in immunocompetent hosts: a series of 11 cases. Scand J Infect Dis. 2006;38:43–8.CrossRefPubMed
44.
Bamberger DM. Successful treatment of multiple cerebral histoplasmomas with itraconazole. Clin Infect Dis. 1999;28:915–6.CrossRefPubMed
45.
Myint T, Anderson AM, Sanchez A, Farabi A, Hage C, Baddley JW, et al. Histoplasmosis in patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS): multicenter study of outcomes and factors associated with relapse. Medicine (Baltimore). 2014;93:11–8.CrossRef
46.
Knapp S, Turnherr M, Dekan G, Willinger B, Stingl G, Rieger A. A case of HIV-associated cerebral histoplasmosis successfully treated with fluconazole. Eur J Clin Microbiol Infect Dis. 1999;8:658–61.CrossRef
47.
Tiraboschi I, Parera IC, Pikielny R, Scattini G, Micheli F. Chronic Histoplasma capsulatum infection of the central nervous system successfully treated with fluconazole. Eur Neurol. 1992;32:70–3.CrossRefPubMed
48.
Klein CJ, Dinapoli RP, Temesgen Z, Meyer FB. Central nervous system histoplasmosis mimicking a brain tumor: difficulties in diagnosis and treatment. Mayo Clin Proc. 1999;18:658–61.
49.
Srinivasan J, Ooi WW. Successful treatment of histoplasmosis brain abscess with voriconazole. Arch Neurol. 2008;65:666.CrossRefPubMed
50.
Prinapori R, Mikulska M, Parisini A, Ratto S, Viscoli C. A case of cerebral histoplasmosis in an immunocompetent host successfully treated with voriconazole. Infect Dis Trop Med. 2015;1:e90–2.
51.
52.
Pitisuttithum P, Negroni R, Graybill JR, Bustamante B, Pappas P, Chapman S, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother. 2005;6:745–55.CrossRef
53.
Restrepo A, Tobon A, Clark B, Graham DR, Cocoran G, Bradsher RW, et al. Salvage treatment of histoplasmosis with posaconazole. J Inf Secur. 2007;54:319–27.
54.
Grim SA, Proia L, Miller R, Alhyraba M, Costas-Chavarri A, Oberholzer J, Clark NM. A multicenter study of histoplasmosis and blastomycosis after solid organ transplantation. Transpl Infect Dis. 2012;14:17–2.CrossRefPubMed
55.
Freifeld AG, Iwen PC, Lesiak BL, Gilroy RK, Stevens RB, Kalil AC. Histoplasmosis in solid organ transplant recipients at a large midwestern university transplant center. Transpl Infect Dis. 2005;7:109–15.CrossRefPubMed
56.
57.
Cuellar-Rodriquez J, Avery RK, Lard M, Budev M, Gordon SM, Shrestha NK, et al. Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplant center in an endemic area. Clin Infect Dis. 2009;49:710–6.CrossRef
58.
Luckett K, Dummer JS, Miller G, Hester S, Thomas L. Histoplasmosis in patients with cell-mediated immunodeficiency: human immunodeficiency virus infection, organ transplanatation, and tumor necrosis factor-a inhibition. Open Forum Infect Dis. 2014; doi:10.​1093/​ofid/​ofu116.PubMedCentral
59.
Goldman M, Zackin R, Fichtenbaum CJ, Skiest DJ, Koletar SL, Hafner R, et al. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clin Infect Dis. 2004;38:1485–9.CrossRefPubMed
60.
Dhawan J, Verma P, Sharma A, Gupta S. Disseminated cutaneous histoplasmosis in an immunocompetent child, relapsed with itraconazole, successfully treated with voriconazole. Ped Dermatol. 2010;27:549–51.CrossRef
61.
Achulze AB, Heptner B, Kessler T, Baumgarten B, Stoica V, Mohr M, et al. Progressive histoplasmosis with hemophagocytic lymphohistiocytosis and epithelioid granulomatosis: a case report and review of the literature. Eur J Haematol. 2017; doi:10.​1111/​ejh.​12886.
62.
Clark B, Foster R, Tunbridge A, Green S. A case of disseminated histoplasmosis successfully treated with the investigational drug posaconazole. J Inf Secur. 2005;51:e177–80.
63.
Manolakos J, Cooray M, Patel A, Haider S. Bats, fever, and adenopathy—what is the link? Can J Infect Dis Med Microbiol. 2013;24:35–7.PubMedPubMedCentral
Metadaten
Titel
Treatment of the Midwestern Endemic Mycoses, Blastomycosis and Histoplasmosis
verfasst von
Carol A. Kauffman
Publikationsdatum
21.06.2017
Verlag
Springer US
Erschienen in
Current Fungal Infection Reports / Ausgabe 3/2017
Print ISSN: 1936-3761
Elektronische ISSN: 1936-377X
DOI
https://doi.org/10.1007/s12281-017-0281-x

Weitere Artikel der Ausgabe 3/2017

Current Fungal Infection Reports 3/2017 Zur Ausgabe

Fungal Infections of Skin and Subcutaneous Tissue (A Bonifaz, Section Editor)

Fungal Leukonychia and Melanonychia: a Review

Fungal Infections of Skin and Subcutaneous Tissue (A Bonifaz, Section Editor)

Onychomycosis Laboratory Diagnosis: Review

Fungal Infections of Skin and Subcutaneous Tissue (A Bonifaz, Section Editor)

Fungal Paronychia. Clinical, Diagnosis and Treatment Aspects

Current Management of Fungal Infections (M Miceli, Section Editor)

Untargeted Antifungal Treatment Strategies for Invasive Candidiasis in Non-neutropenic Critically Ill Patients: Current Evidence and Insights

Current Management of Fungal Infections (M Miceli, Section Editor)

Update on Therapeutic Drug Monitoring of Antifungals for the Prophylaxis and Treatment of Invasive Fungal Infections

Fungal Infections of Skin and Subcutaneous Tissue (A Bonifaz, Section Editor)

The Efficacy and Safety of Systemic Antifungals in Children’s Onychomycosis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise